Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-L1 Expression”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableActive Not RecruitingNCT06876402
What this trial is testing

Gene Molecular Alterations as Disease Prognostic Markers in Patients With Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)
Hellenic Cooperative Oncology Group 367
Testing effectiveness (Phase 2)Active Not RecruitingNCT05445843
What this trial is testing

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Who this might be right for
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Novartis Pharmaceuticals 95
Large-scale testing (Phase 3)Looking for participantsNCT06119581
What this trial is testing

First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell LungNeoplasm Metastasis
Eli Lilly and Company 1,264
Not applicableStudy completedNCT02785562
What this trial is testing

Epidemiologic Multicenter Prospective Study in Advanced NSCLC (Non Small Cell Lung Cancer) Patients With PDL1 (Protein Death Ligand 1) Expression.

Who this might be right for
Lung Cancer
Groupe Francais De Pneumo-Cancerologie 170
Testing effectiveness (Phase 2)UnknownNCT05394233
What this trial is testing

Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC

Who this might be right for
Non-squamous Non-small Cell Lung CancerEGFR Gene Mutation
Sichuan Cancer Hospital and Research Institute 20
Testing effectiveness (Phase 2)UnknownNCT04992715
What this trial is testing

PD-L1 Expression in Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
NanoMab Technology (UK) Limited 15
Not applicableLooking for participantsNCT06754345
What this trial is testing

68Ga-NK224 PET Imaging of PD-L1 Expression in Cancers

Who this might be right for
TumorPD-L1
The First Affiliated Hospital of Xiamen University 100
Not applicableUnknownNCT05595265
What this trial is testing

Expression of Programmed Death Ligand-1 (PD-L1) in Nasopharyngeal and Hyypopharyngeal Carcinoma

Who this might be right for
Nasopharyngeal and Hypopharyngeal Carcinoma
Sohag University 50
Not applicableEnded earlyNCT04082988
What this trial is testing

Early Response Evaluation in NSCLC Patients Treated With Immunotherapy

Who this might be right for
NSCLC, Stage IV
The Netherlands Cancer Institute 9
Not applicableLooking for participantsNCT07396259
What this trial is testing

Predicting Clinical Efficacy of Immunotherapy Using Pre-treatment andContinuousMonitoring of PD-L1 TPS/CPS on CTCs, and Immunity Exhaustion Scores

Who this might be right for
Circulating Tumor Cells (CTCs)ImmunotherapyPD-L1 Expression+1 more
Chang Gung Memorial Hospital 150
Large-scale testing (Phase 3)Study completedNCT02352948
What this trial is testing

A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Who this might be right for
Non - Small Cell Lung Cancer NSCLC
AstraZeneca 597
Large-scale testing (Phase 3)Looking for participantsNCT06561386
What this trial is testing

Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Who this might be right for
Non-small Cell Lung Cancer
Bristol-Myers Squibb 1,000
Not applicableStudy completedNCT03092739
What this trial is testing

Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens

Who this might be right for
Carcinoma, Non-Small-Cell LungCarcinoma, Small Cell
Hoffmann-La Roche 184
Testing effectiveness (Phase 2)UnknownNCT05055167
What this trial is testing

Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC

Who this might be right for
Non-small Cell Lung Cancer Stage IV
The First Affiliated Hospital of Xiamen University 20
Not applicableUnknownNCT03582527
What this trial is testing

PD-L1 Expression in Advanced Osteosarcoma

Who this might be right for
ProgressionSurvival
Peking University People's Hospital 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT06162572
What this trial is testing

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Servier Bio-Innovation LLC 102
Not applicableStudy completedNCT03258788
What this trial is testing

A Translational Study Investigating PD-L1 Expression After Radiotherapy for Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
The Christie NHS Foundation Trust 15
Testing effectiveness (Phase 2)Looking for participantsNCT07523529
What this trial is testing

Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors

Who this might be right for
Advanced UnresectableMetastatic
Beijing Biotech 72
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06982924
What this trial is testing

A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.

Who this might be right for
EGFR Mutation Positive Advanced Non Small Cell Lung CancerPD-L1 Positive
Shanghai Chest Hospital 136
Testing effectiveness (Phase 2)Ended earlyNCT03382899
What this trial is testing

Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Eli Lilly and Company 101
Next Page